NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Natera, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$399.42+5.98 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $57.23B
- P/E (TTM)
- –
- Dividend yield
- –
Natera, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $2.69B | $2.49B | $2.30B | $2.11B | $1.95B | $1.82B | $1.69B | $1.52B | $1.35B | $1.20B | $1.07B | $974.16M | 99.5% | +37.9% |
| Licensing and other revenues | $13.92M | $11.27M | $10.29M | $9.10M | $10.75M | $10.56M | $11.84M | $12.54M | $12.00M | $13.16M | $14.05M | $14.56M | 0.5% | +29.5% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.66B | $2.46B | $2.26B | $2.08B | $1.92B | $1.79B | $1.66B | $1.49B | $1.33B | $1.17B | $1.05B | $956.10M | 98.2% | +38.2% |
| Americas, excluding U.S. | – | – | $9.35M | $6.32M | $6.80M | $6.83M | $6.62M | $6.34M | $5.63M | $5.23M | $4.91M | $4.93M | – | – |
| Asia Pacific and Other | – | – | $8.01M | $7.68M | $9.16M | $8.78M | $8.66M | $8.76M | $6.89M | $6.74M | $7.22M | $7.36M | – | – |
From the segment and revenue-disaggregation notes of Natera's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.